Drugs / IDRX-42
IDRX-42
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07859735 | Nov 2026 → Apr 2028 expected | digestive system neoplasm | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07867171 | Oct 2026 → Sep 2027 expected | digestive system neoplasm | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07862114 | Oct 2026 → Jan 2027 expected | digestive system neoplasm | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05489237 | Aug 2022 → Mar 2027 expected | gastrointestinal stromal tumor, metastatic malignant neoplasm | GSK | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07843641 | Oct 2026 → Jan 2031 expected | digestive system neoplasm | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07689201 | Aug 2026 → Nov 2027 expected | gastrointestinal stromal tumor | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07585266 | Jul 2026 → Aug 2032 expected | gastrointestinal stromal tumor | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07218926 | Dec 2025 → May 2028 expected | gastrointestinal stromal tumor | GlaxoSmithKline | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT07825701 Background | — | gastrointestinal stromal tumor | GlaxoSmithKline | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-26 | GlaxoSmithKline | Results GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA gsk.com ↗
First results for velzatinib in first-line (1L) advanced gastrointestinal stromal tumours (GIST) will show promising activity and tolerability across KIT mutations. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-26 | GlaxoSmithKline | GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA gsk.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDRX-42 | “The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan...” NCT07689201 ↗ |
| Known as | GSK6042981 | “Individual Patient Expanded Access for Velzatinib (GSK6042981) in Patients With Gastrointestinal Stromal Tumours With KIT Mutations” NCT07825701 ↗1“A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy” NCT07218926 ↗ |
| Known as | M-4205 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314917 ↗ |
| Known as | Velzatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07859735 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor” NCT05489237 ↗ |
| Modality | Small molecule | “small molecule” NCT05489237 ↗ |
| Route | Oral | “orally administered” NCT05489237 ↗ |